Clinical Trials
9 trialsNCT03126916 2026-02-27
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Children's Oncology Group
Phase 3 Recruiting
NCT03794349 2026-02-18
Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma
Children's Oncology Group
Phase 2 Active not recruiting
NCT04385277 2025-10-27
Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)
Children's Oncology Group
Phase 2 Active not recruiting
NCT01334515 2019-10-21
Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma
Children's Oncology Group
Phase 2 Completed
NCT00003119 2017-03-13
Surgery in Treating Children With Neuroblastoma
Children's Oncology Group
Phase 3 Completed
NCT00023634 2015-03-06
S0114 Vaccine Therapy in Treating Patients With Gastric, Prostate, or Ovarian Cancer
SWOG Cancer Research Network
Phase 1 Terminated
NCT00003093 2014-08-01
Combination Chemotherapy in Treating Children With Neuroblastoma
Children's Oncology Group
Phase 3 Completed
NCT00002594 2014-07-24
Combination Chemotherapy Followed by Bone Marrow and/or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Medulloblastoma or CNS Germ Cell Tumors
Children's Oncology Group
Phase 2 Completed
NCT00017368 2014-02-13
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Neuroblastoma
Children's Oncology Group
Phase 2 Completed